Sort by
Keyphrases
Randomized Trial
100%
Clear Cell Renal Cell Carcinoma (ccRCC)
100%
Metastatic Renal Cell Carcinoma (mRCC)
100%
Sunitinib
100%
Everolimus
100%
Epigenetic Biomarkers
100%
KDM5C
80%
Confidence Interval
60%
BRCA1-associated Protein 1 (BAP1)
60%
Somatic mutation
60%
MTOR Inhibitor
60%
Vascular Endothelial Growth Factor Inhibitors
60%
PBRM1
60%
Targeted Therapy
40%
Treatment Outcome
40%
Tumor
20%
Clinical Outcomes
20%
Cancer Genes
20%
SETD2
20%
Tumor Samples
20%
Progression-free Survival
20%
Overall Survival
20%
Tumor DNA
20%
Cox Proportional Hazards Model
20%
Tumor Treatment
20%
Predictive Value
20%
Statistical Analysis
20%
Targeted Sequencing
20%
Cancer Study
20%
Tumor mutation Burden
20%
Measurement Analysis
20%
Novel mutation
20%
Kidney Cancer
20%
Log-rank Test
20%
Clear Cell Histology
20%
Nephrectomy
20%
Impact Outcomes
20%
Somatic Treatment
20%
Molecular Subgroups
20%
Heterogeneous Features
20%
Hazard Log
20%
Therapy Outcome
20%
Mutation Impact
20%
Genomic Classification
20%
BAP1 mutation
20%
Correlation Statistics
20%
PBRM1 mutation
20%
Medicine and Dentistry
Biological Marker
100%
Neoplasm
100%
Somatic Mutation
100%
Kidney Metastasis
100%
Sunitinib
100%
Mammalian Target of Rapamycin Inhibitor
100%
Vasculotropin Inhibitor
100%
Everolimus
100%
Targeted Therapy
66%
Treatment Outcome
66%
Malignant Neoplasm
33%
Clear Cell Renal Cell Carcinoma
33%
Progression Free Survival
33%
Overall Survival
33%
Prospective Study
33%
Proportional Hazards Model
33%
Tumor
33%
Kidney Cancer
33%
Clear Cell
33%
Outcome Assessment
33%
Nephrectomy
33%
Log Rank Test
33%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
100%
Biological Marker
100%
Sunitinib
100%
Kidney Metastasis
100%
Mammalian Target of Rapamycin Inhibitor
100%
Vasculotropin Inhibitor
100%
Everolimus
100%
Malignant Neoplasm
33%
Progression Free Survival
33%
Prospective Study
33%
Renal Cell Carcinoma
33%
Overall Survival
33%
Kidney Cancer
33%